177 related articles for article (PubMed ID: 33511085)
1. A Novel Long-Term Graves' Disease Animal Model Confirmed by Functional Thyrotropin Receptor Antibodies.
Diana T; Holthoff HP; Fassbender J; Wüster C; Kanitz M; Kahaly GJ; Ungerer M
Eur Thyroid J; 2020 Dec; 9(Suppl 1):51-58. PubMed ID: 33511085
[TBL] [Abstract][Full Text] [Related]
2. A cyclic peptide significantly improves thyroid function, thyrotropin-receptor antibodies and orbital mucine /collagen content in a long-term Graves' disease mouse model.
Diana T; Ungerer M; Wüster C; Faßbender J; Li Z; Reimann A; Holthoff HP; Kanitz M; Kahaly GJ
J Autoimmun; 2021 Aug; 122():102666. PubMed ID: 34144327
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a Bridge Immunoassay with Two Bioassays for Thyrotropin Receptor Antibody Detection and Differentiation.
Allelein S; Diana T; Ehlers M; Kanitz M; Hermsen D; Schott M; Kahaly GJ
Horm Metab Res; 2019 Jun; 51(6):341-346. PubMed ID: 31207654
[TBL] [Abstract][Full Text] [Related]
4. Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies.
Diana T; Wüster C; Kanitz M; Kahaly GJ
J Endocrinol Invest; 2016 Oct; 39(10):1159-65. PubMed ID: 27197966
[TBL] [Abstract][Full Text] [Related]
5. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa.
McLachlan SM; Rapoport B
Thyroid; 2013 Jan; 23(1):14-24. PubMed ID: 23025526
[TBL] [Abstract][Full Text] [Related]
6. The effect of thyrotropin-receptor blocking antibodies on stimulating autoantibodies from patients with Graves' disease.
Lenzner C; Morgenthaler NG
Thyroid; 2003 Dec; 13(12):1153-61. PubMed ID: 14751037
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease.
Diana T; Krause J; Olivo PD; König J; Kanitz M; Decallonne B; Kahaly GJ
Clin Exp Immunol; 2017 Sep; 189(3):304-309. PubMed ID: 28439882
[TBL] [Abstract][Full Text] [Related]
8. Epitope heterogeneity of thyrotropin receptor-blocking antibodies in Graves' patients as detected with wild-type versus chimeric thyrotropin receptors.
Grasso YZ; Kim MR; Faiman C; Kohn LD; Tahara K; Gupta MK
Thyroid; 1999 Jun; 9(6):531-7. PubMed ID: 10411114
[TBL] [Abstract][Full Text] [Related]
9. A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease.
Hovens GC; Buiting AM; Karperien M; Ballieux BE; van der Pluijm G; Pereira AM; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Apr; 64(4):429-35. PubMed ID: 16584516
[TBL] [Abstract][Full Text] [Related]
10. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
Maugendre D; Massart C
Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of functional thyrotropin receptor antibodies in Serbian patients with Graves' orbitopathy.
Sarić Matutinović M; Diana T; Nedeljković Beleslin B; Ćirić J; Žarković M; Kahaly GJ; Ignjatović S
J Endocrinol Invest; 2022 Jan; 45(1):189-197. PubMed ID: 34324163
[TBL] [Abstract][Full Text] [Related]
12. Neutralization and purification of thyroid stimulating antibody (TSAb) and thyroid blocking antibody (TBAb) by heterophilic antibody to animal IgG in Graves' disease.
Ochi Y; Kajita Y; Hachiya T; Hamaoki M
Endocr J; 2012; 59(1):65-72. PubMed ID: 22082836
[TBL] [Abstract][Full Text] [Related]
13. A novel hypothesis for the etiology of Graves' disease: TSAb may be thyroid stimulating animal IgG-like hormone and TBAb may be the precursor of TSAb.
Ochi Y; Kajita Y; Hachiya T; Hamaoki M
Med Hypotheses; 2012 Jun; 78(6):781-6. PubMed ID: 22472575
[TBL] [Abstract][Full Text] [Related]
14. Role of self-tolerance and chronic stimulation in the long-term persistence of adenovirus-induced thyrotropin receptor antibodies in wild-type and transgenic mice.
McLachlan SM; Aliesky HA; Chen CR; Rapoport B
Thyroid; 2012 Sep; 22(9):931-7. PubMed ID: 22827528
[TBL] [Abstract][Full Text] [Related]
15. Long term persistence of thyrotropin receptor antibodies in wild-type and transgenic mice in a Graves' disease model.
McLachlan SM; Aliesky H; Chen CR; Rapoport B
Thyroid; 2012 Apr; ():. PubMed ID: 22489908
[TBL] [Abstract][Full Text] [Related]
16. Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease.
Kahaly GJ; Diana T; Kanitz M; Frommer L; Olivo PD
J Clin Endocrinol Metab; 2020 Apr; 105(4):e1006-14. PubMed ID: 31865369
[TBL] [Abstract][Full Text] [Related]
17. Thyroid-stimulating antibody assay using a human thyrotropin receptor transfected cell line: relationship to clinical features of graves' disease.
Kim MR; Faiman C; Hoogwerf BJ; Gupta MK
Endocr Pract; 1997; 3(6):337-43. PubMed ID: 15251770
[TBL] [Abstract][Full Text] [Related]
18. Immunological similarity of thyroid stimulating antibody (TSAb) and thyroid blocking antibody (TBAb) with animal IgG.
Ochi Y; Kajita Y; Hachiya T; Hamaoki M
Endocr J; 2012; 59(1):73-9. PubMed ID: 22082835
[TBL] [Abstract][Full Text] [Related]
19. A novel bioassay for anti-thyrotrophin receptor autoantibodies detects both thyroid-blocking and stimulating activity.
Li Y; Kim J; Diana T; Klasen R; Olivo PD; Kahaly GJ
Clin Exp Immunol; 2013 Sep; 173(3):390-7. PubMed ID: 23647395
[TBL] [Abstract][Full Text] [Related]
20. Stimulating and blocking thyroid-stimulating hormone (TSH) receptor autoantibodies from patients with Graves' disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity, and binding sites.
Morgenthaler NG; Ho SC; Minich WB
J Clin Endocrinol Metab; 2007 Mar; 92(3):1058-65. PubMed ID: 17179194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
